PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China

Kai-Jie Wu*, Xin-Qi Pei*, Ge Tian, Da-Peng Wu, Jin-Hai Fan, Yu-Mei Jiang, Da-Lin He

Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) in China; however, the prognostic factors associated with effects in these patients are still controversial. In this study, we retrospectively reviewed the data from 71 eligible Chinese patients who received docetaxel chemotherapy from 2009 to 2016 in our hospital and experienced a reduction of prostate-specific antigen (PSA) level ≥50% during the treatment and investigated the potential role of time to nadir (TTN) of PSA. TTN was defined as the time from start of chemotherapy to the nadir of PSA level during the treatment. Multivariable Cox regression models and Kaplan–Meier analysis were used to predict overall survival (OS). In these patients, the median of TTN was 17 weeks. Patients with TTN ≥17 weeks had a longer response time to chemotherapy compared to TTN <17 weeks (42.83 vs 21.50 weeks, \( P < 0.001 \)). The time to PSA progression in patients with TTN ≥17 weeks was 11.44 weeks compared to 5.63 weeks when TTN was <17 weeks. We found several factors to be associated with OS, including TTN (hazard ratio [HR]: 3.937, 95% confidence interval [CI]: 1.502–10.309, \( P = 0.005 \)), PSA level at the diagnosis of cancer (HR: 4.337, 95% CI: 1.616–11.645, \( P = 0.004 \)), duration of initial androgen deprivation therapy (HR: 2.982, 95% CI: 1.104–8.045, \( P = 0.031 \)), neutrophil-to-lymphocyte ratio (HR: 3.963, 95% CI: 1.380–11.384, \( P = 0.011 \)), and total PSA response (Class 1 [<0 response] compared to Class 2 [0–50% response], HR: 3.978, 95% CI: 1.278–12.387, \( P = 0.017 \)). In conclusion, TTN of PSA remains an important prognostic marker in predicting therapeutic outcome in Chinese population who receive chemotherapy for mCRPC and have >50% PSA remission.

Asian Journal of Andrology (2018) 20, 173–177; doi: 10.4103/aja.aja_34_17; published online: 12 September 2017

Keywords: castration-resistant prostate cancer; chemotherapy; docetaxel; prostate-specific antigen; survival; time to nadir

INTRODUCTION
Prostate cancer (PCa) becomes one of the most prevalent urological malignancies in men from China. Although more and more people with localized PCa are identified and cured after prostate-specific antigen (PSA) screening in the population, most patients have already developed metastatic disease at diagnosis. Androgen deprivation therapy has been the major treatment for advanced or metastatic PCa; however, most patients only respond for a few years and eventually progress to castration-resistant prostate cancer (CRPC).

Docetaxel-based chemotherapy remains the first-line treatment strategy for the patients with metastatic CPRC (mCRPC) and provides a markedly survival benefit based on the data from two large randomized phase III clinical trials (TAX 327 and SWOG 99-16); however, many patients still experience no response to this drug. Therefore, identification of several reliable prognostic factors will provide us an accurate evaluation of the disease and more suitable treatment strategies. Many prognostic factors have been reported to associate with the outcome of patients who received docetaxel for CRPC. For example, clinicopathologic parameters, including Gleason score, presence of visceral metastases, presence of pain, baseline PSA level, hemoglobin, albumin, lactate dehydrogenase (LDH), alkaline phosphatase (ALP), cycles of chemotherapy, neutrophil-to-lymphocyte ratio (NLR), and time to castration resistance, were independent prognostic factors of overall survival (OS) in patients with CRPC after docetaxel treatment. However, few studies have examined its potential role in predicting therapeutic response to docetaxel or other novel targeted drugs (for example, abiraterone...
or enzalutamide) in CRPC. Thomas et al.\textsuperscript{14} reported that the TTN of PSA could predict rapid relapse in men with mCRPC from Western countries receiving docetaxel chemotherapy; however, it is not clear if the same risk factors are equally predictive for the therapeutic response and patient survival between Caucasian and Chinese. In the present study, we performed a retrospective analysis to investigate whether the TTN of PSA was associated with OS in patients with mCRPC receiving docetaxel-based chemotherapy and found a proper threshold of nadir PSA level that may predict the outcome of chemotherapy for Chinese population.

**PATIENTS AND METHODS**

**Patient treatment and ethical approval**

The data from 71 Chinese patients with mCRPC who received three weekly docetaxel following diagnosis at the Department of Urology, The First Affiliated Hospital of Xian Jiaotong University, from January 2009 to October 2016, were retrospectively reviewed. The previous treatment and baseline characteristics of these patients were described in Supplementary Table 1 and 2. Docetaxel chemotherapy cycles were defined as 21-day treatment periods with docetaxel (75 mg m\textsuperscript{2}) administered on day 1 of each treatment cycle, together with prednisone 5 mg twice daily. All patients were treated for ten cycles unless they could not stand the side effect of chemotherapy or gave up for individual reasons. CRPC was diagnosed according to the EAU guideline: (1) castrate serum testosterone <50 ng ml\textsuperscript{-1} or 1.7 nmol l\textsuperscript{-1}; (2) biochemical progression: three consecutive rises of PSA, 1 week apart, resulting in two 50% increases over the nadir, with PSA >2 ng ml\textsuperscript{-1} or radiological progression: the appearance of two or more bone lesions on bone scan or enlargement of a soft-tissue lesion using the Response Evaluation Criteria in Solid Tumors (RECIST).\textsuperscript{15}

Data were retrospectively obtained from medical records: for biochemical and radiological findings, all patients had examined PSA value at each cycle of chemotherapy and once a month after chemotherapy. Bone scan and magnetic resonance imaging (MRI) or computed tomography (CT) were examined at the beginning, after the 5th cycle, and 1 month after the end of chemotherapy. All examinations were repeated every 6 months for the follow-up. Patients without at least a 50% reduction of PSA during chemotherapy were excluded from the study.

Nadir PSA level was the lowest PSA level during chemotherapy. Thus, TTN was the time from the initiation of chemotherapy to the date that the lowest PSA value was recorded.\textsuperscript{14} PSA progression in this study was defined as an increase in PSA of >25% from the nadir. Response to chemotherapy was defined according to the recommendations of Prostate Cancer Work Group 2 (PCWG2).\textsuperscript{13} OS was the time between the initiation of chemotherapy to the death of any cause or the last follow-up.

**Table 1: Baseline characteristics**

| Variable | TTN <17-week group | TTN ≥17-week group | P |
|----------|---------------------|-------------------|---|
| Number of patients, n (%) | 30 (42.3) | 41 (57.7) | 0.757 |
| Age (year, median with range in parentheses) | 71.5 (53–78) | 70 (55–85) | 0.860 |
| Staging, n (%) | 10 (14.1) | 11 (15.5) | 0.680 |
| T1–T2 | 11 (15.5) | 23 (32.4) | 0.860 |
| T4 | 9 (12.7) | 7 (9.9) | 0.235 |
| N0 | 14 (19.7) | 20 (28.2) | 0.505 |
| N1 | 16 (22.5) | 21 (29.6) | 0.860 |
| PSA level at the beginning of cancer (ng ml\textsuperscript{-1}, median with range in parentheses) | 263 (3.99–4437) | 233.7 (0.84–5000) | 0.871 |
| Duration of initial ADT (month, median with range in parentheses) | 17 (5–84) | 17 (3–84) | 0.323 |
| Baseline PSA level (ng ml\textsuperscript{-1}, median with range in parentheses) | 231.5 (22.2–3456) | 167.9 (0.33–5000) | 0.343 |
| Baseline ALP level (mmol l\textsuperscript{-1}, median with range in parentheses) | 146.2 (54.8–960) | 125.8 (25.98–2050.7) | 0.505 |
| Total PSA response, n (%) | 12 (16.9) | 4 (5.6) | 0.033 |
| Class 1: <0 | 5 (7.0) | 4 (5.6) | 0.680 |
| Class 3: >50% | 13 (18.3) | 33 (46.5) | 0.003 |
| Cycles of chemotherapy, n (%) | 16 (22.5) | 13 (18.3) | 0.067 |
| <10 | 14 (19.7) | 28 (39.4) | 0.839 |
| Total ALP response, reduction (% (mean±s.d.) | 42.03±28.67 | 38.74±43.88 | 0.053 |
| Albumin (g l\textsuperscript{-1}, median with range in parentheses) | 41.6 (33.2–49.4) | 40 (27.8–47.4) | 0.451 |
| Hemoglobin (g l\textsuperscript{-1}, median with range in parentheses) | 122 (69–151) | 111 (69–158) | 0.290 |
| Ca\textsuperscript{2+} (mmol l\textsuperscript{-1}, median with range in parentheses) | 2.13 (1.69–2.42) | 2.14 (1.69–2.48) | 0.001 |
| NLR, n (%) | 17 (23.9) | 26 (36.6) | 0.001 |
| <3.3 | 13 (18.3) | 15 (21.1) | 0.290 |
| ≥3.3 | 5.6±3.45 | 11.4±8.41 | 0.001 |
| Time to PSA progression after TTN (week, mean±s.d.) | 15.23±5.04 | 33.85±9.98 | 0.001 |
| Duration of response to chemotherapy, after TTN (week, mean±s.d.) | 21.50±12.17 | 42.83±18.52 | 0.001 |
| Duration of response to chemotherapy, total (week, mean±s.d.) | 31.10±15.20 | 65.24±21.05 | 0.001 |
| Total PSA reduction (% (mean±s.d.) | 7.17±79.01 | 69.15±47.66 | 0.001 |

T1-T2: tumor confined within prostate; T3: tumor extends through the prostatic capsule; T4: tumor fixed or invades the adjacent structures other than seminal vesicles (e.g., bladder, levator muscles, and/or pelvic wall); ADT: androgen deprivation therapy; ALP: alkaline phosphatase; NLR: neutrophil-to-lymphocyte ratio; PSA: prostate-specific antigen; TTN: time to nadir; CI: confidence interval; s.d.: standard deviation.
The study was conducted in accordance with the Declaration of Helsinki and was approved by the local Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University. Informed written consent was obtained from all patients prior to their enrollment in this study.

**Statistical analysis**

Data were summarized by frequency for categorical variables and by median for continuous variables. Association between categorical variables (i.e., stage T, N, or Class 1 [<0], 2 [0–50%], and 3 [>50%] for PSA response) was assessed using the Chi-square test or Fisher’s exact test. The two groups were compared with the Student’s t-test or Kruskal–Wallis test as appropriate, and variables of different groups were compared with the Chi-square test for the differences in mean time for chemotherapy response, PSA progression, total PSA reduction, or other baseline characteristics. OS was estimated using the Kaplan–Meier method and was compared with the log-rank test. All the factors were assessed in uni- and multi-variate models using Cox regression. All statistical analyses were performed with SPSS 18.0 software (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered statistically significant.

**RESULTS**

**Baseline characteristics**

The baseline characteristics of 71 eligible patients were shown in Table 1. At the initiation of chemotherapy, the median age was 71 years (range: 53–85 years). The number of patients staging T1–T2 (tumor confined within prostate), T3 (tumor extends through the prostatic capsule), and T4 (tumor fixed or invades the adjacent structures other than seminal vesicles) was 21 (29.6%), 34 (47.9%), and 16 (22.5%), respectively. All patients had metastatic disease, and 37 (52.1%) had lymphatic metastasis. The median baseline PSA value at the diagnosis of cancer was 239.60 ng ml\(^{-1}\) (range: 0.84–5000 ng ml\(^{-1}\)). The median duration of initial ADT was 17 months (range: 3–84 months). The median baseline PSA level before chemotherapy was 199.20 ng ml\(^{-1}\) (range: 0.33–5000 ng ml\(^{-1}\)), and the median baseline ALP level was 138 mmol l\(^{-1}\) (range: 25.98–2050.70 mmol l\(^{-1}\)). Forty-two (59.2%) patients finished chemotherapy more than ten cycles. Forty-six (64.8%) patients had a PSA value reduction ≥50%, but 16 (22.5%) patients failed. The remaining 71 patients were divided into two groups according to the TTN value during chemotherapy. We chose 17 weeks as the optimal threshold using sensitivity curve based on survival status.

**Table 2: Uni- and multi-variable model analysis of overall survival**

| Variable                        | Category | Univariable HR for death (95% CI) P | Multivariable HR for death (95% CI) P |
|---------------------------------|----------|-------------------------------------|--------------------------------------|
| Age (year)                      | ≥65 vs <65 | 0.956 (0.432–2.115) 0.912 |                                      |
| Staging T                       | T3 vs T1–T2 | 1.848 (0.642–5.405) 0.260 |                                      |
|                                | T4 vs T1–T2 | 1.825 (0.660–5.501) 0.246 |                                      |
| Staging N                       | N1 vs N0  | 1.190 (0.568–2.176) 0.840 |                                      |
| PSA level at the diagnosis of cancer (ng ml\(^{-1}\)) | ≥150.1 vs <150.1 | 2.201 (1.036–4.677) 0.040 | 4.337 (1.616–11.645) 0.004 |
| Duration of initial ADT (months) | ≥18 vs <18 | 0.354 (0.152–0.825) 0.016 | 2.982 (1.104–8.045) 0.031 |
| Baseline PSA level at trial entry (ng ml\(^{-1}\)) | ≥110.7 vs <110.7 | 3.108 (1.077–8.970) 0.036 | 1.280 (0.370–4.425) 0.696 |
| Baseline ALP level at trial entry (mmol l\(^{-1}\)) | ≥85.7 vs <85.7 | 1.762 (0.841–4.840) 0.134 |                                      |
| Number of chemotherapy cycles, (n) | ≥10 vs <10 | 0.425 (0.193–0.933) 0.033 | 1.558 (0.620–3.906) 0.346 |
| Total PSA response, reduction (%) | CL1 vs CL2 | 0.349 (0.137–0.898) 0.027 | 3.978 (1.278–12.387) 0.017 |
|                                | CL1 vs CL3 | 0.428 (0.137–1.330) 0.143 | 1.888 (0.459–7.757) 0.378 |
| Total ALP response, reduction (%) | ≥39.7 vs <39.7 | 0.882 (0.420–1.852) 0.739 |                                      |
| NLR                             | ≥3.3 vs <3.3 | 2.733 (1.259–5.932) 0.011 | 3.963 (1.380–11.384) 0.011 |
| Albumin (g l\(^{-1}\))          | ≥37 vs <37 | 0.917 (0.832–1.01) 0.077 |                                      |
| Hemoglobin (g l\(^{-1}\))       | ≥105 vs <105 | 0.531 (0.252–1.115) 0.094 |                                      |
| Ca\(^{2+}\) (mmol l\(^{-1}\))   | ≥2.11 vs <2.11 | 0.438 (0.207–0.827) 0.031 | 1.166 (0.397–3.420) 0.780 |
| TTN (week)                      | ≥17 vs <17  | 0.311 (0.149–0.650) 0.002 | 3.937 (1.502–10.309) 0.005 |
| Nadir PSA (ng ml\(^{-1}\))      | ≥16.3 vs <16.3 | 1.251 (0.552–2.831) 0.592 |                                      |

CL1: Class 1, PSA response <0; CL2: Class 2, PSA response 0%–50%; CL3: Class 3, PSA response >50%; T1–T2: tumor confined within prostate; T3: tumor extends through the prostatic capsule; T4: tumor fixed or invades the adjacent structures other than seminal vesicles (e.g., bladder, levator muscles, and/or pelvic wall); ADT: androgen deprivation therapy; ALP: alkaline phosphatase; HR: hazard ratio; NLR: neutrophil-to-lymphocyte ratio; PSA: prostate-specific antigen; TTN: time to nadir; CI: confidence interval
TTN ≥17 weeks was 33.85 weeks compared to 15.23 weeks when TTN was <17 weeks (P < 0.001). The total mean duration of response to chemotherapy in patients with TTN ≥17 weeks was 65.24 weeks compared to 31.10 weeks when TTN was <17 weeks (P < 0.001). We should take into consideration that TTN would influence the above results, so we redefined the time to PSA progression and duration of response to chemotherapy without TTN. Compared with TTN <17-week group, patients with longer TTN (≥17 weeks) may have a longer mean time to PSA progression (11.44 weeks vs 5.63 weeks, P < 0.001) and duration of response to chemotherapy (42.83 weeks vs 21.50 weeks, P < 0.001) (Figure 2 and 3). Another factor, i.e., PSA reduction was 69.15% when TTN was ≥17 weeks, but only 7.17% when TTN was <17 weeks (P = 0.009) (Table 1).

**DISCUSSION**

ADT is generally performed and effective for advanced or metastatic PCa until men develop CRPC. Patients with mCRPC have a very poor prognosis, and docetaxel-based chemotherapy has been regarded as the standard treatment.\(^{18}\) Many prognostic factors associated with the treatment efficacy have been reported.\(^{1–7}\) In our previous study, we have also demonstrated that NLR, PSA level at the diagnosis of cancer, number of chemotherapy cycles, and total PSA response were independent prognostic factors on OS and progression-free survival (PFS) of Chinese patients with mCRPC treated with docetaxel.\(^{19}\) In this study, our results further showed that TTN was a strong predictor of OS for these patients in both uni- and multi-variate Cox proportional hazards regression analyses.

Indeed, the measurement of PSA levels is useful for evaluating the therapeutic effects of ADT or chemotherapy in patients with PCa; however, there is no agreement on the prognostic importance of different PSA indexes after treatment. Among PSA indexes, PSA nadir and TTN have been reported as good predictors of disease progression, survival, and therapeutic response in metastatic PCa.\(^{10–13}\) However, there were very few studies to evaluate their potential prognostic roles in docetaxel-based chemotherapy for patients with mCRPC. A retrospective study analyzed the data from 41 consecutive mCRPC patients treated with docetaxel and found that a TTN from the initiation of chemotherapy of <16 weeks was an independent predictor of shorter duration of response.\(^{14}\) Another study reported that PSA kinetic parameters prior to ADT including PSA half-time, PSA level at nadir, duration of nadir, PSA doubling time, and PSA level at the start of chemotherapy were obvious surrogate markers predicting cancer-specific survival (CSS) in patients undergoing docetaxel treatment for CRPC.\(^{20}\) However, the predictive role of TTN in survival of Chinese patients with mCRPC receiving docetaxel-based chemotherapy is still unknown.

Similar with the results from Western countries,\(^{14,20}\) we also found that patients with a longer TTN had a longer response time to chemotherapy and time to PSA progression in this study. Importantly, TTN, duration of initial ADT, and total PSA response were significantly associated with OS of mCRPC patients in a single center from Northwestern China. However, there is still no consensus of both optimal threshold of PSA nadir and cutoff value of TTN after ADT or chemotherapy for predicting survival. Our study selected the median of TTN (17 weeks) as threshold, which was more than 16 weeks reported by the study from the United Kingdom.\(^{14}\) The reason we supposed was that most of the patients from Northwestern China failed to be diagnosed early or treated, so some Chinese patients with mCRPC represent an extremely high level of PSA at the diagnosis of cancer. Therefore, the TTN of PSA in these patients would be longer than men from Western countries. Nevertheless, this retrospective study, based on populations from Northwestern China, demonstrated that TTN was an independent prognostic factor on OS in Chinese patients with mCRPC treated with docetaxel and had >50% PSA remission.

In addition, treatment options for patients with mCRPC following docetaxel-based chemotherapy are rapidly increasing nowadays, and more drugs, including abiraterone acetate, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been shown to improve patient survival, which are available for second-line treatment of CRPC following docetaxel.\(^{21–26}\) Therefore, it would be helpful to identify...
patients with mCRPC who initially respond to docetaxel-based chemotherapy but are at a high risk of rapid disease relapse. Herein, our study suggests that patients with TTN <17 weeks after chemotherapy might be expected to have a shorter PFS, indicating that these patients should be re-evaluated earlier and should be considered for a new treatment strategy such as abiraterone or enzalutamide to get the maximum survival benefit.

CONCLUSIONS
This study provided a potential association between TTN and the outcome of patients with mCRPC who received docetaxel-based chemotherapy; however, we should not neglect the limitation of this study. It was only an open-labeled, nonrandomized or historically controlled study with limited sample size. In addition, extremely high level of PSA at the diagnosis of PCa was one of the characteristics of CRPC population in Northwestern China, which might bring some deviation to our results. Hence, we need to further continue our study with a larger sample of population.

AUTHOR CONTRIBUTIONS
KJW and XQP designed the study, analyzed and interpreted the clinical data, wrote and revised the manuscript. KJW, XQP, GT, DPW, JHF, and YMJ collected the clinical data and engaged in patient follow-up. DLH supervised the project and revised the manuscript. All the listed authors have participated actively in the study. All authors read and approved the final manuscript.

COMPETING INTERESTS
All authors declare no competing interests.

ACKNOWLEDGMENTS
This study was partially supported by the National Natural Science Foundation of China (NSFC 81202014 to KJW; NSFC 81130041 to DLH) and the Fundamental Research Funds for the Central Universities (to KJW).

Supplementary information is linked to the online version of the paper on the Asian Journal of Andrology website.

REFERENCES
1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–32.
2. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34–45.
3. Petrylak DP, Tangen CM, Hussain MH, Lara PJ, Jones JA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513–20.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–12.
5. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232–7.
6. Qu YY, Dai B, Kong Y, Ye DW, Yao XD, et al. Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl 2013; 15: 110–5.
7. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972–82.
8. Ercole CJ, Lange PH, Mathisen M, Choue RK, Reddy PK. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987; 138: 1181–4.
9. Mulders PF, Fernandez DM, Theeuwes AG, Oosterhof GO, van Berkel HT. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol 1992; 21: 2–5.
10. Choueiri TK, Xie W, D’Amico AV, Ross RW, Hu JC, et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009; 115: 981–7.
11. Hong SY, Cho DS, Kim SI, Ahn HS, Kim SJ. Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer. Korean J Urol 2012; 53: 607–13.
12. Sasaki T, Onishi T, Hoshina A. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer Prostatic Dis 2011; 14: 248–52.
13. Tomioka A, Tanaka N, Yoshihaka M, Miyake M, Anai S, et al. Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. BMC Urol 2014; 14: 33.
14. Thomas BM, Smith C, Evans J, Button MR, Kumar S, et al. Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. Med Oncol 2013; 30: 719.
15. Cornford P, Bellmunt J, Bolia M, Briers E, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017; 71: 630–42.
16. Scher HI, Halyani S, Tannock I, Morris M, Sternberg CN, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148–59.
17. Sonpavde G, Pond GR, Armstrong AJ, Galsky MD, Leopold L, et al. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU Int 2014; 114: E25–31.
18. Plante KA, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 2005; 55: 300–18.
19. Pei XQ, He DL, Tian G, Lu W, Jiang YM, et al. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-lymphocyte ratio in patients from Northwestern China. Int Urol Nephrol 2017; 49: 629–35.
20. Kim M, Lee J, Jeong CW, Ku JH, Kim HH. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer. Urol Oncol 2015; 33: 201–3.
21. Pezaro C, Attard G. Prostate cancer in 2011: redefining the therapeutic landscape for CRPC. Nat Rev Urol 2012; 9: 63–4.
22. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005.
23. Scher HI, Fizazi K, Saad F, Taplin ME, Stembreg CN, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187–97.
24. Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol 2013; 63: 97–82.
25. Higano CS, Scher HI, Bunch PA, Nemunaitis J, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670–9.
26. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014; 15: 738–46.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

©The Author(s)(2017)
Supplementary Table 1: Previous treatment of 71 metastatic castration-resistant prostate cancer patients

| Treatment                  | TTN ≥17-week group (n) | TTN <17-week group (n) | Total (n) |
|----------------------------|------------------------|------------------------|-----------|
| ADT                        | 29                     | 23                     | 52        |
| ADT + radiotherapy         | 10                     | 5                      | 15        |
| ADT + surgery              | 2                      | 2                      | 4         |

ADT: androgen deprivation therapy; mCRPC: metastatic castration-resistant prostate cancer; TTN: time to nadir

Supplementary Table 2: Baseline characteristics of 71 metastatic castration-resistant prostate cancer patients

|                                | TTN <17-week group (%) | TTN ≥17-week group (%) | Total (%) |
|--------------------------------|-------------------------|------------------------|-----------|
| Number of patients, n (%)      | 30 (42.3)               | 41 (57.7)              | 71        |
| Age (year, median with range in parentheses) | 71.5 (53-78)            | 70 (55-85)             | 71 (53-85) |
| Staging, n (%)                 |                         |                        |           |
| T1–T2                          | 10 (14.1)               | 11 (15.5)              | 21 (29.6) |
| T3                             | 11 (15.5)               | 23 (32.4)              | 34 (47.9) |
| T4                             | 9 (12.7)                | 7 (9.9)                | 16 (22.5) |
| N0                             | 14 (19.7)               | 20 (28.2)              | 34 (47.9) |
| N1                             | 16 (22.5)               | 21 (29.6)              | 37 (52.1) |
| PSA level at the beginning of cancer (ng ml⁻¹, median with range in parentheses) | 263 (3.99–4437)         | 233.7 (0.84–5000)     | 239.6 (0.84–5000) |
| Duration of initial ADT (months, median with range in parentheses) | 17 (5–84)               | 17 (3–84)              | 17 (3–84) |
| Baseline PSA level (ng ml⁻¹, median with range in parentheses) | 231.5 (22.2–3456)       | 167.9 (0.33–5000)     | 199.2 (0.33–5000) |
| Baseline ALP level (mmol l⁻¹, median with range in parentheses) | 146.2 (54.8–960)        | 125.8 (25.98–2050.7)  | 138 (25.98–2050.7) |
| Total PSA response, n (%)      |                         |                        |           |
| Class 1: <0                   | 12 (16.9)               | 4 (5.6)                | 16 (22.5) |
| Class 2: 0%–50%               | 5 (7.0)                 | 4 (5.6)                | 9 (12.7)  |
| Class 3: >50%                 | 13 (18.3)               | 33 (46.5)              | 46 (64.8) |
| Cycles of chemotherapy, n (%)  |                         |                        |           |
| <10                            | 16 (22.5)               | 13 (18.3)              | 29 (40.8) |
| ≥10                            | 14 (19.7)               | 28 (39.4)              | 42 (51.2) |
| Total ALP response, reduction (% mean±s.d.) | 42.03±28.67             | 38.74±43.88            | 0.839     |
| Albumin (g l⁻¹, median with range in parentheses) | 41.6 (33.2–49.4)        | 40 (27.8–47.4)         | 0.053     |
| Hemoglobin (g l⁻¹, median with range in parentheses) | 122 (69–151)            | 111 (69–158)           | 0.451     |
| Ca²⁺ (mmol l⁻¹, median with range in parentheses) | 2.13 (1.69–2.42)        | 2.14 (1.69–2.48)       | 0.290     |
| NLR, n (%)                    |                         |                        |           |
| <3.3                          | 17 (23.9)               | 26 (36.6)              | 43 (60.6) |
| ≥3.3                          | 18 (25.3)               | 15 (21.1)              | 33 (46.4) |

T1–T2: tumor confined within prostate; T3: tumor extends through the prostatic capsule; T4: tumor fixed or invades the adjacent structures other than seminal vesicles (e.g., bladder, levator muscles, and/or pelvic wall); ADT: androgen deprivation therapy; ALP: alkaline phosphatase; NLR: neutrophil-to-lymphocyte ratio; PSA: prostate-specific antigen; TTN: time to nadir; s.d.: standard deviation